Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 45 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

357 Mechanisms of LGALS3BP-driven resistance to TIL therapy

5 affiliations
  1. 1Massachusetts General Hospital, Boston, MA, USA
  2. 21Massachusetts General Hospital, Boston, MA, USA
  3. 3Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
  4. 4Mass General Brigham Cancer Institute, Boston, Massachusetts, USA
  5. 5Medical University of South Carolina, Charleston, SC, USA

Related

  1. Therapy-Induced Senescence in Cancer Treatment Resistance: Mechanisms, Evidence, and Translational Opportunities
    Jose-Ramon Blanco, Amancio Carnero
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Shining a Light on the Mechanisms of Drug Resistance to Anti-PD-1 Therapy in Non-small Cell Lung Cancer.
    Hongsheng Guo, Mengmeng Jiang, Hailian Zhang +2
    Human mutationPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  3. Resistance mechanisms and translational bottlenecks in CAR-T cell therapy for pediatric acute lymphoblastic leukemia: a perspective
    JiLi Xu, Lili Sui, Wenzhe Yang +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.
    Chao Wang, Dong Yang
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Antimicrobial Therapy, Disinfection, Resistance Mechanisms, and Microbiota Interactions in Nontuberculous Mycobacteria: Current Evidence and Emerging Perspectives.
    Morteza Ghazanfari Jajin, Abolfazl Fateh
    Infection and drug resistancePeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMCPMC
BibTeX
@article{lawless2026mechanisms,
  title = {{357 Mechanisms of LGALS3BP-driven resistance to TIL therapy}},
  author = {Aleigha Lawless and Tatyana Sharova and Moshe Sade-Feldman and Hongyan Xie and Jacy Fang and Sonia Cohen and Genevieve M Boland and Sarah E San Vicente and Russell W Jenkins},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0357},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0357},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 357 Mechanisms of LGALS3BP-driven resistance to TIL therapy
AU  - Aleigha Lawless
AU  - Tatyana Sharova
AU  - Moshe Sade-Feldman
AU  - Hongyan Xie
AU  - Jacy Fang
AU  - Sonia Cohen
AU  - Genevieve M Boland
AU  - Sarah E San Vicente
AU  - Russell W Jenkins
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0357
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0357
SN  - 2051-1426
ER  -